Cas:690632-69-0 1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride manufacturer & supplier

Chemical Name:1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride

CAS.NO:690632-69-0

Synonyms:1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride

Molecular Formula:C₁₂H₁₀ClF₃N₂O

Molecular Weight:290.66900

HS Code:

Physical and Chemical Properties:

Melting point:102ºC

Boiling point:126.9ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:34.89000

Exact Mass:290.04300

LogP:4.01500

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride Use and application,1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride technical grade,usp/ep/jp grade.

Related News: Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. 1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride vendor Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections. 1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride factory Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.